Published in Vaccine Weekly, October 4th, 2006
According to recent research from England, "Ovarian cancer commonly relapses after remission and new strategies to target microscopic residual diseases are required. One approach is to activate tumor-specific cytotoxic T cells with dendritic cells loaded with tumor cells."
"In order to enhance their immunogenicity, ovarian tumor cells (SKOV3, which express two well-characterized antigens HER-2/neu and MUC-1) were killed by oxidation with hypochlorous acid (HOCl). Treatment for one hour with 60 micromolar...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly